U.S. Transportation Stock News

AZZ (AZZ) has put up a busy run of quarters ahead of its Q3 2026 report, with Q3 fiscal revenue at US$425.7 million and basic EPS of US$1.37, sitting alongside trailing 12 month revenue of about US$1.6 billion and EPS of US$10.73. Over recent periods the company has seen quarterly revenue move from US$403.7 million in Q3 2025 to US$351.9 million in Q4 2025, then into the US$422.0 million to US$425.7 million range in Q1 to Q3 2026, while basic EPS has ranged from US$0.68 in Q4 2025 to US$5.71...

If you are wondering whether Ventas at around US$75 is offering good value today, you are not alone. This article is designed to help you size that up clearly. The stock has pulled back recently, with a 3% decline over the last 7 days and a 6.2% decline over the last 30 days. The 1 year return sits at 32.5%, the 3 year at 66.9%, and the 5 year at 83.8%. Recent attention on Ventas has focused on its position in the healthcare real estate sector and how investors view that exposure as interest...

If you are wondering whether UDR is priced attractively today, this article walks through what the current numbers suggest about the stock's value. UDR recently closed at US$37.32, with returns of 1.7% over the last week, 6.9% over the last month, 1.7% year to date, and a 5.4% decline over the past year. This gives a mixed picture of recent performance. Recent coverage around UDR has focused on how investors are reassessing listed residential real estate, with pricing and capital allocation...

If you are wondering whether Block's current share price lines up with its underlying worth, you are not alone. This article is built to help you weigh that question clearly. Block's stock last closed at US$70.16, with returns of 7.8% over the past week, 14.0% over the past month, 7.7% year to date, and a 19.1% decline over the past year, as well as 2.3% and 69.9% declines over the last 3 and 5 years respectively. Recent headlines for Block have focused on its role in digital payments and...

Arbe Robotics recently announced at CES 2026 that it is combining its automotive-grade ultra‑HD radar with NVIDIA’s accelerated computing to create an AI-based perception platform designed for hands-off, eyes-off driving, featuring over 20,000 detections per frame and more than 300 meters of range in varied weather conditions. A distinctive aspect of this development is how the dense radar point cloud, processed on NVIDIA’s in-vehicle computing, is being used to build AI-based occupancy...

Recent reaffirmations of positive ratings on Parker-Hannifin (PH) have put fresh attention on the industrial supplier, as analysts react to its steady financial results, dividends, and push into higher margin aerospace and motion control markets. See our latest analysis for Parker-Hannifin. The reaffirmed positive sentiment from analysts has arrived alongside solid recent momentum, with a 90 day share price return of 26.49% and a 1 year total shareholder return of 42.68%, suggesting interest...

Jefferies coverage initiation puts Goosehead Insurance in focus Jefferies has initiated coverage on Goosehead Insurance (GSHD), highlighting the company’s low-risk expansion through independent agency partnerships, its position in the property and casualty market, and a broker model focused on retention and commissions. See our latest analysis for Goosehead Insurance. Goosehead Insurance’s share price has moved to US$74.80, with a 90-day share price return of 9.09%. The 1-year total...

If you are wondering whether XPeng's current share price still offers value, you are not alone. This article is built to help you weigh what the market might be pricing in. XPeng shares last closed at US$20.52, with returns of 1.2% over 7 days, 3.6% over 30 days, 0.4% year to date, 69.0% over 1 year and 103.0% over 3 years, while the 5 year return stands at a 59.2% decline. Recent coverage of XPeng has focused on its position in the electric vehicle space and the market's changing...

Q3 revenue surprise puts XPEL (XPEL) back in focus Recent attention on XPEL (XPEL) stems from its Q3 results, where revenue growth surpassed expectations while earnings per share came in below forecasts. This has prompted investors to reassess the trade off between sales momentum and profitability. See our latest analysis for XPEL. At a share price of $54.63, XPEL has climbed sharply in recent months, with a 90 day share price return of 61.18% and a 1 year total shareholder return of 39.35%...

On 9 January 2026, Schrödinger, Inc. announced a collaboration with Eli Lilly’s TuneLab platform, integrating TuneLab’s AI-driven drug discovery workflows into Schrödinger’s LiveDesign enterprise informatics environment via a privacy-preserving federated learning framework. This arrangement highlights Schrödinger’s role within a wider ecosystem of leading AI and machine-learning providers supporting Lilly’s efforts to accelerate drug discovery while keeping partner data separate and...

First Interstate BancSystem (FIBK) is drawing fresh attention as several analysts turn more optimistic on the regional bank, citing improving sector conditions and loan growth prospects in connection with its upcoming quarterly earnings report. See our latest analysis for First Interstate BancSystem. The recent analyst upgrades and upcoming earnings call sit against a stronger price backdrop, with a 23.58% 90 day share price return and a 25.47% 1 year total shareholder return suggesting...

Webull (BULL) is drawing fresh attention after its Australian subsidiary launched Vega AI, an AI-powered investment assistant that offers real-time market analysis, 24/7 decision support, and streamlined financial report summaries for local users. See our latest analysis for Webull. Vega AI arrives at a time when Webull’s short term momentum has been mixed, with a 7-day share price return of 8.49% and a 30-day share price return of a 17.76% decline, while the 1-year total shareholder return...

Tecnoglass (TGLS) shares fell 5.5% after the company issued full-year EBITDA guidance that investors viewed as weak. At the same time, competitor Apogee Enterprises cut its outlook, reinforcing concerns about demand and cost pressures. See our latest analysis for Tecnoglass. At a share price of $51.23, Tecnoglass has a 1-day share price return of 6.86%, but a 90-day share price return decline of 17.46% and a 1-year total shareholder return loss of 30.55%, suggesting momentum has been fading...

If you are wondering whether Cal-Maine Foods at around US$75.46 is offering good value or asking too much, you are exactly who this review is written for. The stock has seen a 5.2% decline over the last 7 days, a 12.5% decline over 30 days, a 3.8% decline year to date and a 21.3% decline over 1 year. The 3 year and 5 year returns sit at 70.5% and 160.0% respectively. Recent attention on egg producers, shifts in consumer prices and ongoing discussion about food inflation have kept Cal-Maine...

For investors wondering whether Karman Holdings at around US$101.28 represents an opportunity or is already fully valued, this article walks through what the numbers may indicate about the stock. The share price has been active recently, with returns of 38.4% over the past 7 days, 58.9% over the past 30 days and 31.8% year to date. These movements can influence how you think about potential upside and risk. Recent coverage of Karman Holdings has focused on its listing on the NYSE and growing...

BofA recently reiterated a positive view on Sana Biotechnology, citing supportive sector trends such as increased large-cap biopharma dealmaking and improved capital access for cell and gene therapy developers. At the same time, Sana confirmed it will provide a business update at the past 44th Annual J.P. Morgan Healthcare Conference, highlighting growing investor interest in its engineered cell therapy platforms. We’ll now examine how BofA’s constructive sector commentary, alongside Sana’s...

Wondering if Accenture at around US$281.82 is priced for opportunity or caution right now? This article walks through what the numbers are saying about value. The stock has returned 5.0% over the last 7 days and 4.6% over the last 30 days, while the 1 year return sits at a 19.6% decline and the 5 year return at 19.1%. Recent news flow around Accenture has focused on its role in technology consulting and services and how clients are using the company for large scale digital projects. That...

If you are wondering whether Walker & Dunlop is attractively priced at its current level, this article will walk through what the numbers are saying about its valuation. The stock last closed at US$62.36, with returns of 3.7% over the past week, 0.0% over the last month, 6.2% year to date, and a 29.9% decline over the past year. This sits against a 24.8% decline over three years and a 21.4% decline over five years. Recent attention on Walker & Dunlop has been shaped by ongoing market views...

Century Communities (CCS) recently highlighted its growth plans with the launch of two new residential communities: Crawford Ridge in Alabama and Willow Glenn in Washington, supported by its fully online homebuying platform. See our latest analysis for Century Communities. These new communities and the focus on online homebuying arrive during a period of improving share price momentum, with a 1-day share price return of 6.8% and a 90-day share price return of 6.7%, while the 1-year total...

If you are wondering whether Vicor's sharp share price run still lines up with its underlying value, you are not alone. Vicor shares last closed at US$136.11, with returns of 24.2% over 7 days, 37.1% over 30 days, 16.5% year to date, 176.2% over 1 year and 124.0% over 3 years, compared to 34.2% over 5 years. Recent trading has been shaped by news flow around the company, including ongoing investor attention on its role in the capital goods sector and how its technology fits into power...

Jazz Pharmaceuticals recently reported positive Phase 3 HERIZON-GEA-01 results for its HER2-targeted therapy Ziihera (zanidatamab-hrii) in combination with chemotherapy, showing a statistically significant survival benefit over trastuzumab plus chemotherapy in adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. By positioning Ziihera as a potential new standard of care and supporting an upcoming FDA submission, this data could meaningfully reshape Jazz’s...

If you are wondering whether Regeneron Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. This article is built to help you think through that question clearly. Over the last week the stock returned 3.8%, over the last month it returned 15.7%, and over the last year it returned 9.8%. These figures may catch the eye of investors thinking about both opportunity and risk. Alongside those returns, investors have been watching ongoing developments around...

If you are wondering whether VICI Properties at around US$27.86 is priced fairly or offering value, you are in the right place for a clear look at what the market might be implying. The stock has been relatively steady recently, with a 0.4% return over 30 days, a slight 1.0% decline year to date, and a modest 2.3% return over the last year, on top of a 42.8% return across the past 5 years. Those moves sit alongside a mixed medium term picture, where VICI Properties shows a 3.5% decline over...

First Citizens BancShares (FCNC.A) has drawn investor attention after recent share price moves, with the stock showing positive returns over the past month and past 3 months. That, together with solid profitability figures, is prompting closer scrutiny. See our latest analysis for First Citizens BancShares. Those near term share price gains sit alongside a stronger backdrop, with a 90 day share price return of 27.97% and a 3 year total shareholder return of 165.29%. This suggests momentum has...